12:00 AM
 | 
Sep 15, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Asentar: Development halted

After reviewing information submitted by Novacea, FDA lifted the clinical hold on Asentar in place since November 2007, after the company terminated the Phase III ASCENT-2 trial due to a higher death rate among AIPC patients receiving Asentar plus ...

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >